Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G’s Q3: Negative Pricing, ‘Change In Tone’ Have Analysts Spooked

Executive Summary

Firm’s slowing organic growth and negative pricing impacts in the third quarter reflect much-talked-about pressures in health and beauty care. However, the scope of the challenges is becoming clearer, and analysts are questioning whether P&G’s “not business as usual” response will be enough.

Advertisement

Related Content

IFF’s $7.1bn Frutarom Buy Shows Market Shifts Rippling Up The Supply Chain
P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint
P&G Goes Native In Acquisition That Aligns With Peltz' Vision
P&G May Be Simpler, More Efficient, But Investors Anxious For Growth

Topics

Advertisement
UsernamePublicRestriction

Register

RS121580

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel